Esperion Therapeutics Inc. (Nasdaq: ESPR) reported a wider than expected loss for the first quarter and announced positive results from Phase 3 study of bempedoic acid but 13 patients died. The stock price plummeted $24.75 to close at $45.75.
Esperion Therapeutics reports loss
May 02, 2018 at 19:16 PM EDT
